

## **Minor sarcoplasmic reticulum membrane components that modulate excitation-contraction coupling in striated muscles**

Susan Treves<sup>1,2</sup> Mirko Vukcevic<sup>1</sup>, Marcin Maj<sup>1</sup>, Raphael Thurnheer<sup>1</sup> and Francesco Zorzato<sup>2\*</sup>

<sup>1</sup>Departments of Anesthesia and Biomedicine, Basel University Hospital, Hebelstrasse 20, 4031 Basel, Switzerland

<sup>2</sup>Department of Experimental and Diagnostic Medicine, University of Ferrara, Via Borsari 46, 44100 Ferrara, Italy

To whom correspondence should be addressed:

- Prof. Francesco Zorzato
- Department of Experimental and Diagnostic Medicine
- University of Ferrara, Via Borsari 46, 44100 Ferrara, Italy
- Tel. +39-0532-455356
- E-mail: [zor@unife.it](mailto:zor@unife.it)

- **Abstract**

Alterations of  $\text{Ca}^{2+}$  signaling have been linked to several genetic neuromuscular diseases, thus it is important to uncover the toolkit components and intracellular pathways involved in  $\text{Ca}^{2+}$  signaling under normal and pathological conditions.

### **Calcium homeostasis in striated muscles**

Over the decades, the role(s) played by  $\text{Ca}^{2+}$  in skeletal muscle have been unveiled and it is now clearly established that it is the key molecule underlying muscle contraction. Its importance is given by the fact that movement of the contractile proteins is dependent on the  $\text{Ca}^{2+}$  released from the sarcoplasmic reticulum (SR), an organelle constituting approximately 10% of the cell's volume and fully dedicated to uptake and release of  $\text{Ca}^{2+}$  (Peachey, 1965; Volpe, 1991). The SR can be structurally divided into two distinct portions: the terminal cisternae, which face the transverse tubules (an invagination of the plasma membrane) and the longitudinal sarcoplasmic reticulum, connecting two terminal cisternae. The terminal cisternae can be further divided into junctional face membrane (the domain facing the transverse tubules) and non junctional membrane (Saito, 1984; Costello, 1986).

Depolarization of the plasma membrane of skeletal muscle leads to release of  $\text{Ca}^{2+}$  from the SR resulting in muscle contraction, by a process known as excitation-contraction coupling (Schneider, 1972; Melzer, 1995; Berchtold, 2000). Excitation-contraction coupling (EC coupling) occurs at the triad, a structure composed of the two membrane compartments, transverse tubules containing the voltage sensing dihydropyridine receptor (DHPR, an L-type  $\text{Ca}^{2+}$  channel) and terminal cisternae on which ryanodine receptor (RyR)  $\text{Ca}^{2+}$  release channels are localized (Mitchell, 1983; Rios 1991). The disposition of DHPRs and RyRs on their respective membranes is highly ordered and each RyR tetramer faces alternative rows of DHPRs (figure 1) (Block, 1988; Franzini-Armstrong, 1994; Paolini, 2004). These two  $\text{Ca}^{2+}$  channels are the basic unit underlying excitation-contraction coupling but they do not function alone, but rather can be thought of as macromolecular structures, composed of a number of accessory proteins involved in their fine regulation.

## **Major and minor protein components of the sarcoplasmic reticulum**

One of the major advances in the field of excitation-contraction coupling was the development of reproducible procedures enabling the fractionation of SR membranes enriched in proteins involved in calcium handling (Campbell, 1980; Meissner, 1973; Saito, 1984). This revealed that protein components of the longitudinal SR (LSR) and terminal cisternae are different, reflecting the functional subspecialization of these membrane fractions, which are respectively,  $\text{Ca}^{2+}$  uptake and  $\text{Ca}^{2+}$  release. Figure 2 shows a 5-15% SDS PAG stained with Coomassie Brilliant Blue of the protein components of LSR, terminal cisternae and junctional face membrane. The major component of the LSR constituting approximately 80% of the total proteins present, is the 110 kDa CaATPase (SERCA), i.e. the pump responsible for pumping the  $\text{Ca}^{2+}$  released by the RyR1s back into the SR. The 22kDa protein band present in the longitudinal SR fraction is phospholamban, a protein involved in regulating the activity of the SERCA pump in heart and slow twitch muscle fibers. When phospholamban is dephosphorylated, it inhibits the activity of SERCA, whereas in its phosphorylated state, inhibition is relieved (Slack, 1997; Liu, 1997; MacLennan, 2003). Ablation of phospholamban causes a significant (25%) decrease in the time to half relaxation of isolated solei with no change in the contraction time (Jay, 1997), supporting its important role in regulating of SERCA activity.

Two glycoproteins of 160 kDa (sarcalumenin) and 53 kDa (53 kDa glycoprotein) represent minor protein constituents of the LSR membrane fraction and are generated by alternative splicing of the same transcript, which is expressed both in heart and skeletal muscle. The large transcript (sarcalumenin) is a low affinity ( $k_D = 0.6$  mM) high capacity (35 mol/mol protein)  $\text{Ca}^{2+}$  binding protein, while the shorter product of 53 kDa, lacks the  $\text{NH}_2$  and thus the  $\text{Ca}^{2+}$  binding domain. Sarcalumenin is involved in the maintenance of the SERCA protein as illustrated by the fact that sarcalumenin KO animals exhibit significant decreased SERCA activity and SERCA protein content (Leberer, 1990; Yoshida, 2005).

As shown in figure 2, the protein composition of the JFM is far more complex than that of the LSR (Costello, 1986); aside the most abundant components, including the ryanodine receptor (RyR), calsequestrin (CsQ), histidine rich  $\text{Ca}^{2+}$  binding protein and

traidin(s) (TRISK) which will not be discussed in this review, there are a number of other minor protein components whose function has recently been unraveled or that still await functional characterization. Much work has focused on the identification of the full set of protein constituents of the junctional face membrane (JFM) and on understanding their functional role in excitation-contraction coupling. Two main approaches have been used to characterize the minor membrane-protein components at the molecular, cellular and functional level: (i) the immuno-proteomic approach utilized by Takeshima's lab, which combines production of monoclonal Abs against membrane proteins selected on the base of specific triadic immunostaining of muscle sections, cDNA cloning, expression and biochemical analysis of identified proteins to gene knock out techniques (Weisleder, 2008). (ii) Junctional face membrane purification or heparin agarose chromatography and identification of proteins co-eluting with the RyR, combined with Western blotting, Mass Spec analysis and peptide sequencing (Divet, 2005). These approaches have been relatively successful and at least 5 minor membrane protein components that will be described in the next section, have been identified and characterized.

### **Mitsugumin-29:**

This is a 29 kDa membrane protein related to the synaptophysin-family, originally identified in the SR of skeletal muscle and in the endoplasmic reticulum of kidney renal tubules (Shimuta, 1998). Analysis of its primary sequence, as well as biochemical and ultrastructural evidence suggest that mitsugumin-29 contains 4 transmembrane spanning domains and that it is localized in the transverse tubules of mature skeletal muscles where it self-associates as hexamers (Shimuta, 1998; Brandt, 2001). Though mitsugumin-29 does not tightly associate with other proteins, experimental evidence suggests that it can functionally interact with the RyR1, whereby it increases RyR1 open probability without affecting channel current amplitude (Pan, 2004). Muscles isolated from mitsugumin-29 KO mice exhibit swollen transverse tubules, vacuolated SR and misaligned triadic structures. These ultrastructural changes are accompanied by dysfunctional  $\text{Ca}^{2+}$  handling; specifically, the intracellular  $\text{Ca}^{2+}$  stores of myotubes from mitsugumin-29 KO mice deplete more rapidly and refill more slowly after depolarization than myotubes from control mice (Pan, 2002). Such alterations lead to “global” functional changes, so that

muscles from mitsugumin-29 KO mice fatigue more rapidly than their wild type counterpart (Nagaraj, 2000). Taken together these results suggest that mitsugumin-29 functions as a tethering structure, forcing the transverse tubules into a conformation, which favors the formation of triadic structures. Lack of integral triads then leads to altered  $\text{Ca}^{2+}$  handling and defective SOC-dependent  $\text{Ca}^{2+}$  influx.

### **Junctophilin-1:**

Junctophilins are membrane spanning proteins with a large cytoplasmic region containing a 14 amino acid repeat motif (MORN motif) with selective binding affinity for the plasma membrane and a carboxy-terminal transmembrane segment spanning the ER/SR (Takeshima, 2000). At least three isoforms encoded by distinct genes, exist: junctophilin-1 is specifically expressed in skeletal muscle, junctophilin-2 is expressed in the heart, in skeletal muscles and in smooth muscles and junctophilin-3 is expressed in the brain (Nishi, 2000). In skeletal muscle junctophilin-1 (72 kDa protein) is involved in physically linking the transverse tubules to the SR membrane. Protein overlay and surface plasmon assays suggest that it achieves this by interacting with phospholipids, especially with sphingomyelin and phosphatidylcholine, rather than through protein-protein interactions (Weisler, 2008). Ablation of junctophilin-1 severely affects muscle function leading homozygous KO mice to premature death within 20 h after birth. Ultrastructural examination of the skeletal muscles of junctophilin-1 KO mice shows morphological abnormalities, including incomplete formation of the junctional complexes between transverse tubules and the SR, swollen terminal cisternae and reduced numbers of triads. As a consequence muscles develop less contractile force after electrical stimulation and show abnormal sensitivity to extracellular  $\text{Ca}^{2+}$  (Ito, 2001; Komazaki, 2002).

### **SRP-27/TRIC-A:**

Mitsugumin-33 or TRIC-A (trimeric intracellular cation-selective channel) (Yazawa, 2007) also known as SRP-27 (sarcoplasmic reticulum protein of 27 kDa) (Bleunven, 2008) is expressed in excitable tissues and is particularly enriched in fast twitch skeletal muscles, where its expression level peaks after 2 months of post-natal development. Mice lacking TRIC/SRP-27 are viable and display no overt phenotype.

Double-labeling immunocytochemistry experiments of mouse muscle fibers indicate that SRP-27 is localized in the perinuclear endoplasmic reticulum as well as in a SR subcompartment, which is adjacent to, but distinct from, that containing the RyR1 and SERCA (Bleunven, 2008). Interestingly, SRP-27/TRIC-A could be pulled-down by beads coated with maurocalcine and RyR1, but not with maurocalcine alone, raising the possibility that SRP-27/TRIC-A is part of the RyR1 macromolecular complex (Bleunven, 2008). Hydrophobicity plots and biochemical analysis also revealed that TRIC-A/SRP-27 is an integral ER/SR protein containing up to three membrane spanning domains, whose amino-terminus is located in the lumen of the ER/SR and whose carboxy terminus is exposed to the cytoplasm. Sequence comparison also predicts the presence of an ion-conducting pore between the first and second transmembrane domains and cross-linking experiments demonstrate that TRIC-A/SRP-27 tends to form homo-oligomers (dimers and trimers). Three dimensional reconstruction studies of the native protein suggest that it acquires a pyramidal elongated structure, similar to that of bacterial porin channels (Yazawa, 2007). Interestingly, reconstitution in lipid bilayers, suggest that TRIC-A/SRP-27 is a cation channel, with a selectivity of  $K^+$  over  $Na^+$  (permeability ratio  $P_K/P_{Na} = 1.5$ ) (Yazawa, 2007). To gain more insight into the function of this channel, Yazawa (2007) followed changes in the membrane potential of isolated muscle fibers from control and TRIC-A/SRP-27 KO mice. The lack of TRIC-A/SRP-27 reduced the  $K^+$  permeability accompanying thapsigargin-induced  $Ca^{2+}$  efflux, without affecting  $Ca^{2+}$  permeability, suggesting that this protein may act as a monovalent-cation channel. Such a channel could be activated physiologically during RyR1-mediated  $Ca^{2+}$  release to counter-balance the charge movement due to efflux of  $Ca^{2+}$  (Somlyo, 1981), which would otherwise leave the SR lumen with a negative charge. However, the role of TRIC-A/SRP-27 as a monovalent-cation countercurrent channel during  $Ca^{2+}$  release has been challenged by data of Gillespie and Fill (Gillespie, 2008) which indicates that the RyR1 channel mediates its own potassium countercurrent during SR  $Ca^{2+}$  release. This would obviate the need of an additional countercurrent carrier during SR  $Ca^{2+}$  release, leaving the exact functional role of TRIC-A/SRP-27 controversial.

JP-45 is a 45 kDa polypeptide containing a single transmembrane segment, which is highly enriched in skeletal muscle junctional face membrane where its expression is developmentally regulated, reaching maximal levels during the second month of post-natal development (Anderson, 2003). Originally JP-45 was identified as a protein weakly phosphorylated by cAMP dependent protein kinase and co-eluting with the RyR1 and DHPR from a heparin-agarose column (Zorzato, 2000). Surprisingly however, co-immunoprecipitation experiments revealed that JP-45 is not part of the RyR1 macromolecular complex, but rather it interacts with calsequestrin via its luminal carboxy-terminal domain and with  $Ca_v1.1$ , through its cytoplasmic amino terminus (Anderson, 2003). Extensive pulldown and co-immunoprecipitation experiments, revealed that JP-45 binds to different regions on the  $Ca_v1.1$ , namely to its carboxy-terminus and to a region within the I-II loop referred to as AID, where the  $\beta 1a$  subunit also binds (Anderson, 2006). The interaction between  $Ca_v1.1$  and  $\beta 1a$  is thought to be essential for targeting or stabilizing  $Ca_v1.1$  on the plasma membrane (Flucher, 2002).

Several approaches have been exploited to unravel the function of JP-45 in skeletal muscle: (i) acute over-expression and depletion of JP-45 in differentiated C2C12 myotubes (Anderson, 2006; Gouadon, 2006) and (ii) chronic depletion in JP-45 knock out mice (Delbono, 2007). Interestingly both over-expression and ablation of JP-45 result in a decrease of voltage-dependent  $Ca^{2+}$  release. This effect could be due to a decrease of functional expression of the  $Ca_v1.1$  on the transverse tubules (Anderson, 2006; Delbono, 2007). Alternatively, the effect on  $Ca^{2+}$  release may be linked to alterations of the interaction of JP-45 with calsequestrin. Gouadon (2006) showed that low levels of JP-45 over-expression affect the permeability of the  $Ca^{2+}$  release unit by altering excitation-contraction coupling transfer function (Gouadon, 2006). Given that the luminal carboxy-terminus of JP-45 binds to calsequestrin, it is possible that JP-45 constitutes a key protein for a signalling pathway between calsequestrin and  $Ca_v1.1$ . Over-expression of JP-45 may result in the accumulation of JP-45 molecules which are not associated with calsequestrin, and this in turn may send an inhibitory signal to the  $Ca_v1.1$ .

Interestingly the skeletal muscle phenotype of young JP-45 KO mice, is reminiscent of that of aged mice. During mouse ageing, the membrane density of the voltage sensor ( $Ca_v1.1$ ), the SR membrane content of JP-45 and the  $Ca^{2+}$  currents of muscle membranes

are significantly lower compared to those of young animals (Anderson, 2006; Delbono, 1995; Gonzales, 2003; Renganathan 1997, 1998). These data suggest that both  $Ca_v1.1$  and JP-45 may be important for the maintenance of muscle strength, and indicate that JP-45 KO mice may be a useful experimental model to investigate alteration of excitation contraction coupling linked to ageing.

### **Junctate/ humbug**

Junctate is a 33 kDa protein with a single ER/SR membrane spanning domain, expressed in a variety of excitable and non-excitable tissues (Treves, 2000; Dinchuk, 2000; Hong, 2001). Figure 3A shows how transcripts deriving from the same gene (*BAH* or *A $\beta$ H-J-J* locus) located on human chromosome 8q12.1 can give rise to four distinct classes of proteins via a complex pattern of alternative splicing. Though the complexity of *A $\beta$ H-J-J* locus is more the exception than the rule, it illustrates how important it is to precisely establish the number and type of gene products when deciding to create knock out animal models of protein(s) encoded by the *BAH* gene.

Figure 3B illustrates schematically how the different polypeptides are assembled to yield: (i) junctin, a structural calsequestrin binding protein present in cardiac and skeletal muscle SR that forms a quaternary complex with triadin, RyR1 and calsequestrin (Jones, 1995; Kagari, 1996; Zhang, 1997). (ii) Aspartyl- $\beta$ -hydroxylase an enzyme catalyzing posttranslational hydroxylation of aspartate and asparagine residues within epidermal growth factor-like domains present in receptors and receptor ligands involved in cell growth and differentiation, and extracellular matrix molecules (Stenflo, 1989; Gronke 1989; Monkovic, 1992). (iii) Junctate, a moderate affinity ( $K_D$  217  $\mu$ M), high capacity (21 moles  $Ca^{2+}$ /mole protein)  $Ca^{2+}$  binding protein (Treves, 2000). (iv) Humbug, a truncated version of aspartyl- $\beta$ -hydroxylase, lacking its catalytic domain, which shares with junctate the high capacity moderate affinity  $Ca^{2+}$  binding domain (Dinchuk, 2000; Treves, 2000; Hong, 2001). Analysis of the genomic organization of the *A $\beta$ H-J-J* locus has revealed the presence of two distinct promoters P1 and P2 (Feriotto, 2006) that are regulated by specific transcription factors, giving rise to polypeptides with distinct amino-termini and tissue distribution. Transcripts starting from exon 1 (green box in fig.3A), which is under the control of the P1 promoter, are expressed in most tissues and

share their NH<sub>2</sub> terminus with aspartyl-β-hydroxylase (Treves, 2000; Dinchuk, 2000; Feriotta, 2007). Exon 1a (blue box in fig. 3A) is approximately 8 kb downstream from exon 1 and is under the control of the P2 promoter whose induction is controlled by the muscle specific transcription factor MEF-2 (Feriotta, 2005). Transcripts starting from this exon are expressed in striated muscles and share their NH<sub>2</sub> termini with junctin/junctate (Treves, 2000; Dinchuk, 2000). Exon 2 encodes the transmembrane domain (yellow box in fig.3A) and together with exon 3, is shared by all family members deriving from the AβH-J-J locus. The carboxy-terminal portion of the proteins depends on which exons are transcribed: junctin results from transcription of exons 4a and 5a, while all other products are generated via transcription of exons 4-24 and result in a variety of products of different sizes. The longer transcripts give rise to the enzyme aspartyl-β-hydroxylase with an apparent molecular mass of approximately 120 kDa. The shorter transcripts generate proteins with molecular masses ranging from 40 to 53 kDa which share the acidic Ca<sup>2+</sup> binding domain (Treves, 2000; Dinchuk, 2000; Hong, 2001). Heart expresses junctin and junctate, as well as humbug and aspartyl-β-hydroxylase (Treves, 2000; Dinchuk, 2000; Hong, 2001). Interestingly, humbug is also highly expressed in a variety of invasive human tumors and its level of expression has been suggested to be useful as a prognostic marker for cancer progression (Ince, 2000; Palumbo, 2002; Maeda, 2004; Xian, 2006; Wang, 2007; Lee, 2008).

In the rest of this section only the functional properties of junctate will be discussed, and the reader is referred to other articles describing the function of aspartyl-β-hydroxylase and junctin (Gronke, 1989; Wang, 2007; Jones, 1995; Kagari, 1996; Zhang, 1997). Because of its calcium binding properties, a number of approaches were undertaken to define the potential role of junctate in Ca<sup>2+</sup> homeostasis: (i) acute over-expression and depletion junctate from cultured cells (Treves, 2000; Treves, 2004) and (ii) chronic over-expression of junctate in skeletal muscles (Divet, 2007) and heart (Hong, 2008). Acute over-expression of junctate in COS-7 and HEK293 cells is accompanied by significant functional and structural changes of the ER membrane. Specifically, in HEK cells over-expressing TRPC3 channels (HEKT3) over-expression of junctate induces extensive proliferation of the ER resulting in significantly larger and more frequent couplings between the ER and the plasma membrane (Treves, 2004). The

induction of ER plasma membrane couplings by junctate is in agreement with co-immunoprecipitation data showing that junctate forms a supramolecular complex with InsP3R and TRPC channels. These structural changes are paralleled by alterations of  $\text{Ca}^{2+}$  homeostasis, specifically by increased peak  $\text{Ca}^{2+}$  release and store-depletion activated  $\text{Ca}^{2+}$  influx; on the other hand, knocking down junctate results in diminished agonist induced peak  $[\text{Ca}^{2+}]_i$  transients and store depletion activated  $\text{Ca}^{2+}$  influx (Treves, 2000, 2004). The increase of store depletion-activated  $\text{Ca}^{2+}$  influx is mediated by the short cytoplasmic  $\text{NH}_2$ -terminal domain of the protein, while the luminal carboxy-terminus  $\text{Ca}^{2+}$ -binding domain of junctate (and thus also of humbug) increases the  $\text{Ca}^{2+}$  content of ER/SR stores and affects calcium transients evoked by SERCA inhibitors.

As to the effect of chronic over-expression of junctate, some discrepancies have arisen from the transgenic mouse models. Over-expression in skeletal muscles does not lead to an overt phenotype but is accompanied by a small increase in  $\text{Ca}^{2+}$  loading and  $\text{Ca}^{2+}$  storage of the SR resulting in a significant increase in RyR1 mediated  $\text{Ca}^{2+}$  release and an increased  $\text{Ca}^{2+}$  influx following depletion of intracellular  $\text{Ca}^{2+}$  stores (Divet, 2007). These changes were attributed to the over-expression of junctate's  $\text{Ca}^{2+}$  binding sites since the expression levels of other SR  $\text{Ca}^{2+}$  handling proteins such as SERCA, calsequestrin or sarcoplumennin were not changed. Interestingly, the increased  $\text{Ca}^{2+}$  cycling across the SR membrane was accompanied by an adaptive increase in the number of mitochondria in fast fibres of EDL (but not soleus) muscles, which was not due to fast-to-slow fibre type transition (Divet, 2007). Junctate over-expression in the heart on the other hand, leads to severe cardiac hypertrophy, bradycardia and arrhythmias as well alterations in the expression level of the SR proteins SERCA2, calsequestrin-2 and calreticulin. This decreased SR content of  $\text{Ca}^{2+}$  handling proteins is accompanied by an up-regulation of the  $\text{Na}^+/\text{Ca}^{2+}$  exchanger and plasmalemma calcium pump, two components of the cardiac sarcolemma involved in extrusion of  $\text{Ca}^{2+}$  from the cytoplasm. The decrease of the major calcium binding proteins of cardiac SR is paralleled by a decrease in caffeine induced  $\text{Ca}^{2+}$  release indicating a lower cardiac  $\text{Ca}^{2+}$  SR loading. At the moment the reasons for these apparent opposite effects of junctate over-expression in the heart and in skeletal muscle have not yet been elucidated.

## **Conclusions**

The past three decades have seen major advancements in our understanding the role of skeletal muscle SR proteins in excitation-contraction coupling. The use of genetically modified animal models has also taught us that few of these proteins, namely the ryanodine receptor, Cav1.1 and junctophyllin, are essential for EC coupling. On the other hand, the minor protein components seem to be important for the regulation of the EC coupling machinery. Mouse and cellular models have also shown that acute and/or chronic over-expression/depletion of a variety of minor components do not result in lethal phenotypes and/or in severe damage of to the EC coupling machinery, suggesting that its fine regulation is provided by functionally redundant minor components. The comprehension of EC coupling and its involvement in the pathophysiology of neuromuscular disorders awaits the identification and functional characterisation of the complete array of proteins of the transverse tubule and junctional face membrane compartments.

**Acknowledgements**

This work was supported by the Swiss National Science Foundation (SNF grant number SNF 3200BO-114597), by the Fondation Suisse de Recherche sur les maladies musculaires, by the Association Française contre les Myopathies and by Telethon Italy.

## References:

Anderson AA, Treves S, Biral D, Betto R, Sandonà D, Ronjat M & Zorzato F (2003). The novel skeletal muscle sarcoplasmic reticulum JP-45 protein. Molecular cloning, tissue distribution, developmental expression, and interaction with alpha 1.1 subunit of the voltage-gated calcium channel. *J Biol Chem* 278, 39987-39992.

Anderson AA, Altafaj X, Zheng Z, Wang ZM, Delbono O, Ronjat M, Treves S & Zorzato F (2006). The junctional SR protein JP-45 affects the functional expression of the voltage-dependent Ca<sup>2+</sup> channel Cav1.1. *J Cell Sci* 119, 2145-2155.

Berchtold MW, Brinkmeier H & Müntener M (2000). Calcium ion in skeletal muscle: its crucial role for muscle function, plasticity and disease. *Physiol Rev* 80, 1215-1265.

Bleunven C, Treves S, Jinyu X, Leo E, Ronjat M, De Waard M, Kern G, Flucher BE & Zorzato F (2008). SRP-27 is a novel component of the supramolecular signalling complex involved in skeletal muscle excitation-contraction coupling. *Biochem J* 411, 343-349.

Block BA, Imagawa T, Campbell KP & Franzini-Armstrong C (1988). Structural evidence for direct interaction between the molecular components of the transverse tubule/sarcoplasmic reticulum junction in skeletal muscle. *J Cell Biol* 107, 2587-2600.

Brandt N, Franklin G, Brunschwig JP & Caswell A (2001) The role of mitsugumin 29 in transverse tubules of rabbit skeletal muscle. *Arch Biochem Biophys* 385, 406-409.

Campbell KP, Franzini-Armstrong C & Shamo AE (1980) Further characterization of light and heavy sarcoplasmic reticulum vesicles. Identification of the sarcoplasmic reticulum feet associated with heavy sarcoplasmic reticulum vesicles. *Biochim Biophys Acta* 602, 97-116.

Costello B, Chadwick C, Saito A, Chu A & Fleischer S (1986). Characterization of the junctional face membrane from terminal cisternae of sarcoplasmic reticulum. *J Cell Biol* 103, 741-753.

Delbono O, O'Rourke KS & Ettinger WH (1995). Excitation-calcium release uncoupling in aged single human skeletal muscle fibers *Journal of Membrane Biology*, 148, 211-222.

Delbono O, Xia J, Treves S, Wang ZM, Jimenez-Moreno R, Payne AM, Messi ML, Brigueat A, Schaerer F, Nishi M, Takeshima H & Zorzato F (2007). Loss of skeletal muscle strength by ablation of the sarcoplasmic reticulum protein JP45. *Proc Natl Acad Sci USA* 104, 20108-20113.

Dinchuk JE, Henderson NL, Burn TC, Huber R, Ho SP, Link J, O'Neil KT, Focht RJ, Scully MS, Hollis JM, Hollis GF & Friedman PA (2000). Aspartyl beta -hydroxylase (Asph) and an evolutionarily conserved isoform of Asph missing the catalytic domain share exons with junctin. *J Biol Chem* 275, 39543-39554.

Divet A, Paesante S, Bleunven C, Anderson A, Treves S & Zorzato F (2005). Novel sarco(endo)plasmic reticulum proteins and calcium homeostasis in striated muscles. *J Muscle Res Cell Motil* 26, 7-12.

Divet A, Paesante S, Grasso C, Cavagna D, Tiveron C, Paolini C, Protasi F, Huchet-Cadiou C, Treves S & Zorzato F (2007). Increased Ca<sup>2+</sup> storage capacity of the skeletal muscle sarcoplasmic reticulum of transgenic mice over-expressing membrane bound calcium binding protein junctate. *J Cell Physiol* 213, 464-474.

Feriotto G, Finotti A, Volpe P, Treves S, Ferrari S, Angelelli C, Zorzato F & Gambari R (2005). Myocyte enhancer factor 2 activates promoter sequences of the human AbetaH-J-J locus, encoding aspartyl-beta-hydroxylase, junctin, and junctate. *Mol Cell Biol* 25, 3261-3275.

Feriotto G, Finotti A, Breveglieri G, Treves S, Zorzato F & Gambari R (2006). Multiple levels of control of the expression of the human A beta H-J-J locus encoding aspartyl-beta-hydroxylase, junctin, and junctate. *Ann NY Acad Sci* 1091, 184-190.

Feriotto G, Finotti A, Breveglieri G, Treves S, Zorzato F & Gambari R (2007). Transcriptional activity and Sp 1/3 transcription factor binding to the P1 promoter sequences of the human AbetaH-J-J locus. *FEBS J* 274, 4476-4490.

Gillespie D & Fill M (2008). Intracellular calcium release channels mediate their own countercurrent: the ryanodine receptor case study. *Biophys J* 95, 3706-3714.

Flucher BE, Weiss RG & Grabner M (2002). Cooperation of two-domain Ca(2+) channel fragments in triad targeting and restoration of excitation- contraction coupling in skeletal muscle. *Proc Natl Acad Sci USA* 99, 10167-10172.

Franzini-Armstrong C & Jorgensen AO (1994) Structure and development of E-C coupling units in skeletal muscle. *Ann Rev Physiol* 56, 509-534.

González E, Messi L, Zheng Z & Delbono O(2003). Insulin-like growth factor-1 prevents age-related decrease in specific force and intracellular Ca<sup>2+</sup> in single intact muscle fibres from transgenic mice. *J Physiol* 552, 833-844.

Gouadon E, Schuhmeier RP, Ursu D, Anderson AA, Treves S, Zorzato F, Lehmann-Horn F, & Melzer W (2006). A possible role of the junctional face protein JP-45 in modulating Ca<sup>2+</sup> release in skeletal muscle. *J Physiol* 572, 269-280.

Gronke RS, VanDusen WJ, Garsky VM, Jacobs JW, Sardana MK, Stern AM & Friedman PA (1989). Aspartyl beta-hydroxylase: in vitro hydroxylation of a synthetic peptide based on the structure of the first growth factor-like domain of human factor IX. *Proc Natl Acad Sci USA* 86, 3609-3613.

Hong CS, Kwak YG, Ji JH, Chae SW & Kim DH (2001). Molecular cloning and characterization of mouse cardiac junctate isoforms. *Biochem Biophys Res Commun* 289, 882-887.

Hong CS, Kwon SJ, Cho MC, Kwak YG, Ha KC, Hong B, Li H, Chae SW, Chai OH, Song CH, Li Y, Kim JC, Woo SH, Lee SY, Lee CO & Kim do H (2008). Overexpression of junctate induces cardiac hypertrophy and arrhythmia via altered calcium handling. *J. Mol Cell Cardiol* 44, 672-682.

Ince N, de la Monte SM & Wands JR (2000). Overexpression of human aspartyl (asparaginyl) beta-hydroxylase is associated with malignant transformation. *Cancer Res* 60, 1261-1266.

Ito K, Komazaki S, Sasamoto K, Yoshida M, Nishi M, Kitamura K & Takeshima H (2001). Deficiency of triad junction and contraction in mutant skeletal muscle lacking junctophilin type 1. *J Cell Biol* 154, 1059-1067.

Jay SP, Grupp IL, Luo W & Kranias EG (1997). Phospholamban ablation enhances relaxation in the murine soleus. *Am J Physiol* 42, C1-C6.

Jones LR, Zhang L, Sanborn K, Jorgensen AO & Kelley J (1995). Purification, primary structure, and immunological characterization of the 26-kDa calsequestrin binding protein (junctin) from cardiac junctional sarcoplasmic reticulum. *J Biol Chem* 270. 30787-30796.

Kagari T, Yamaguchi N & Kasai M (1996). Biochemical characterization of calsequestrin-binding 30-kDa protein in sarcoplasmic reticulum of skeletal muscle. *Biochem Biophys Res Commun* 227, 700-706.

Komazaki S, Ito K, Takeshima H & Nakamura H (2002). Deficiency of triad

formation in developing skeletal muscle cells lacking junctophilin type 1. FEBS Lett 524, 225-229.

Leberer E, Timms BG, Campbell KP & MacLennan DH (1990). Purification, calcium binding properties, and ultrastructural localization of the 53,000- and 160,000 (sarcalumenin)-dalton glycoproteins of the sarcoplasmic reticulum. J. Biol Chem 265, 10118-10124.

Lee JH (2008). Overexpression of humbug promotes malignant progression in human gastric cancer cells. Oncol rep 19,795-800.

Liu Y, Kranias EG, Schneider MF (1997). Regulation of Ca<sup>2+</sup> handling by phosphorylation status in mouse fast- and slow-twitch skeletal muscle fibers. Am J Physiol 273. C1915-C1924.

MacLennan DH, Asahi M & Tupling AR (2003). The regulation of SERCA-type pumps by phospholamban and sarcolipin. Ann NY Acad Sci 986, 472-480.

Maeda T, Taguchi K, Aishima S, Shimada M, Hintz D, Larusso N, Gores G, Tsuneyoshi M, Sugimachi K, Wands JR & de la Monte SM (2004). Clinicopathological correlates of aspartyl (asparaginy) beta-hydroxylase over-expression in cholangiocarcinoma. Cancer Detect Prev 28, 313-318.

Meissner G, Conner GE & Fliescher S (1973). Isolation of sarcoplasmic reticulum by zonal centrifugation and purification of Ca<sup>2+</sup> pump and Ca<sup>2+</sup>-binding proteins. Biochim Biophys Acta 298:246-269.

Melzer W, Hermann-Frank A & Luttgau HC (1995). The role of Ca<sup>2+</sup> ions in excitation-contraction coupling of skeletal muscle fibres. Biochim. Biophys Acta 1241, 59-116.

Mitchell RD, Saito A, Palade P & Fleischer S (1983) Morphology of isolated triads. *J Cell Biol* 96, 1017-1029.

Monkovic DD, VanDusen WJ, Petroski CJ, Garsky VM, Sardana MK, Zavodszky P, Stern AM & Friedman PA (1992). Invertebrate aspartyl/asparaginyl beta-hydroxylase: potential modification of endogenous epidermal growth factor-like modules. *Biochem Biophys Res Commun* 189, 233-241.

Nagaraj RY, Nosek CM, Brotto MA, Nishi M, Takeshima H, Nosek TM & Ma J (2000). Increased susceptibility to fatigue of slow- and fast-twitch muscles from mice lacking the MG29 gene. *Physiol Genomics* 4, 43-49.

Nishi M, Mizushima A, Nakagawara K & Takeshima H (2000). Characterization of human junctophilin subtype genes. *Biochem Biophys Res Commun* 273, 920-927.

Palumbo KS, Wands JR, Safran H, King T, Carlson RI & de la Monte SM (2002). Human aspartyl (asparaginyl) beta-hydroxylase monoclonal antibodies: potential biomarkers for pancreatic carcinoma. *Pancreas* 26, 39-44.

Pan Z, Yang D, Nagaraj RY, Nosek TA, Nishi M, Takeshima H, Cheng H & Ma J (2002). Dysfunction of store-operated calcium channel in muscle cells lacking mg29. *Nat Cell Biol* 4, 379-383.

Pan Z, Hirata Y, Nagaraj RY, Zhao J, Nishi M, Hayek SM, Bhat MB, Takeshima H & Ma J (2004). Co-expression of MG29 and ryanodine receptor leads to apoptotic cell death: effect mediated by intracellular Ca<sup>2+</sup> release. *J Biol Chem* 279, 19387-19390.

Paolini C, Protasi F & Franzini-Armstrong C (2004). The relative position of RyR feet and DHPR tetrads in skeletal muscle. *J Mol Biol* 342, 145-153.

Peachey LD (1965) The sarcoplasmic reticulum and transverse tubules of the frog's

sartorius. *J Cell Biol* 25S, 209-231.

Renganathan M, Messi ML & Delbono O (1997). Dihydropyridine receptor-ryanodine receptor uncoupling in aged skeletal muscle. *J Membr Biol* 157, 247-253.

Renganathan M, Messi ML & Delbono O (1998). Overexpression of IGF-1 exclusively in skeletal muscle prevents age-related decline in the number of dihydropyridine receptors. *J Biol Chem* 273, 28845-28851.

Rios E & Pizarro G (1991). Voltage sensor of excitation-contraction coupling in skeletal muscle. *Physiol Rev* 71, 849-908.

Saito A, Seiler S, Chu A & Fleischer S (1984). Preparation and morphology of sarcoplasmic reticulum terminal cisternae from rabbit skeletal muscle. *J Cell Biol* 99, 875-885.

Schneider MF & Chandler WK (1972). Voltage dependent charge movement of skeletal muscle: a possible step in excitation-contraction coupling. *Nature* 242, 244-246.

Shimuta M, Komazaki S, Nishi M, Iino M, Nakagawara K & Takeshima H (1998). Structure and expression of mitsugumin 29 gene. *FEBS Lett* 43, 263-267.

Slack JP, Grupp IL, Luo W & Kranias EG (1997). Phospholamban ablation enhances relaxation in the murine soleus. *Am J Physiol* 273, C1-C6.

Somlyo AV, Gonzalez-Serratos HG, Shuman H, McClellan G & Somlyo AP (1981). Calcium release and ionic changes in the sarcoplasmic reticulum of tetanized muscle: an electron-probe study. *J Cell Biol* 90, 577-594.

Stenflo J, Holme E, Lindstedt S, Chandramouli N, Huang LH, Tam JP & Merrifield RB (1989). Hydroxylation of aspartic acid in domains homologous to the epidermal

growth factor precursor is catalyzed by a 2-oxoglutarate-dependent dioxygenase. *Proc Natl Acad Sci USA* 86, 444-447.

Takeshima H, Komazaki S, Nishi M, Iino M & Kangawa K (2000). Junctophilins: a novel family of junctional membrane complex proteins. *Mol Cell* 6, 11-22.

Treves S, Feriotto G, Moccagatta L, Gambari R & Zorzato F (2000). Molecular cloning, expression, functional characterization, chromosomal localization, and gene structure of junctate, a novel integral calcium binding protein of sarco(endo)plasmic reticulum membrane. *J Biol Chem* 275, 39555-39568.

Treves S, Franzini-Armstrong C, Moccagatta L, Arnoult C, Grasso C, Schrum A, Ducreux S, Zhu MX, Mikoshiba K, Girard T, Smida-Rezgui S, Ronjat M & Zorzato F (2004). Junctate is a key element in calcium entry induced by activation of InsP3 receptors and/or calcium store depletion. *J Biol Chem* 279, 537-548.

Volpe P & Simon BJ. (1991). The bulk of Ca<sup>2+</sup> released to the myoplasm is free in the sarcoplasmic reticulum and does not unbind from calsequestrin. *FEBS Lett* 278, 274-278.

Wang J, de la Monte SM, Sabo E, Kethu S, Tavares R, Branda M, Simao L, Wands JR & Resnick MB (2007). Prognostic value of humbug gene overexpression in stage II colon cancer. *Hum Pathol* 38, 17-25.

Weisler N, Takeshima H & Ma J (2008). Immuno-proteomic approach to excitation--contraction coupling in skeletal and cardiac muscle: molecular insights revealed by the mitsugumins. *Cell Calcium* 43, 1-8.

Xian ZH, Zhang SH, Cong WM, Yan HX, Wang K & Wu MC (2006). Expression of aspartyl beta-hydroxylase and its clinicopathological significance in hepatocellular carcinoma. *Mod Pathol* 19, 280-286.

Yazawa M, Ferrante C, Feng J, Mio K, Ogura T, Zhang M, Lin PH, Pan Z, Komazaki S, Kato K, Nishi M, Zhao X, Weisleder N, Sato C, Ma J & Takeshima H (2007). TRIC channels are essential for Ca<sup>2+</sup> handling in intracellular stores. *Nature* 448, 78-82.

Yoshida M, Minamisawa S, Shimura M, Komazaki S, Kume H, Zhang M, Matsumura K, Nishi M, Saito M, Saeki Y, Ishikawa Y, Yanagisawa T & Takeshima H (2005). Impaired Ca<sup>2+</sup> store functions in skeletal and cardiac muscle cells from sarcoplumenin-deficient mice. *J Biol Chem* 280, 3500-3506.

Zhang L, Kelley J, Schmeisser G, Kobayashi YM & Jones LR (1997). Complex formation between junctin, triadin, calsequestrin, and the ryanodine receptor. Proteins of the cardiac junctional sarcoplasmic reticulum membrane. *J Biol Chem* 272, 23389-23397.

Zorzato F, Margreth A & Volpe P (1986). Direct photoaffinity labeling of junctional sarcoplasmic reticulum with [<sup>14</sup>C]Doxorubicin. *J Biol Chem* 261, 13252-13257.

Zorzato F, Anderson AA, Ohlendieck K, Froemming G, Guerrini R & Treves S (2000). Identification of a novel 45 kDa protein (JP-45) from rabbit sarcoplasmic-reticulum junctional-face membrane. *Biochem J* 351, 537-543.


## **FIGURE LEGENDS:**

**Figure 1: Schematic representation of the protein components of skeletal muscle sarcoplasmic reticulum.**

**Figure 2: Coomassie Brilliant Blue stained gradient (5-15%) SDS PAGE of protein components present in the longitudinal sarcoplasmic reticulum (LSR), in terminal cisternae (TC) and in the junctional face membrane (JFM) fractions obtained from rabbit SR. (reproduced from figure 2, Zorzato 1986).**

**Figure 3: Genomic organization, splicing pattern and main protein products deriving from of the A- $\beta$ -J-J locus. Panel A: (reproduced from figure 4, Dinchunk, 2000). Coloured boxes represent different exons. Products deriving from exon 1 (green box) give rise to  $\beta$ -aspartyl-hydroxylase/humbug; products deriving from exon 1b (light blue) give rise to junctin/junctate. Yellow box encodes the transmembrane domain. Panel B: schematic representation of the 4 main proteins (junctin, junctate, aspartyl- $\beta$ -hydroxylase and humbug) derived by assembling the different exons (colors of the protein domains match those of the exons from which they are derived).**


**Figure 1**



- |        |           |            |                 |
|--------|-----------|------------|-----------------|
| 1 RyR  | 4 SERCA   | 7 JP-45    | 10 SRP-27/TRIC  |
| 2 DHPR | 5 TRISC   | 8 Junctate | 11 junctophilin |
| 3 CSQ  | 6 junctin | 9 MG-29    |                 |

**Figure 2**

## **Protein composition of skeletal muscle sarcotubular membranes**



**Figure 3**

